Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Ryan Michael Carr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5762-367X; OpenAlex author ID A5002789721. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 3 papers

Papers 14

  1. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  2. Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Last author DOI 10.1158/1078-0432.ccr-25-4968↗
  3. Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0343022↗
  4. Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.semradonc.2025.07.007↗
  5. Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. Co-author DOI 10.1172/jci.insight.187799↗
  6. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  7. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Co-author DOI 10.1530/erc-24-0142↗
  8. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  9. Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2022.06.005↗
  10. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. First author DOI 10.1016/j.pan.2019.11.011↗
  11. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  12. It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-0490↗
  13. Toward personalized TGFβ inhibition for pancreatic cancer. Co-author DOI 10.15252/emmm.201911414↗
  14. Pancreatic cancer microenvironment, to target or not to target? Co-author DOI 10.15252/emmm.201505948↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martín E. Fernández-Zapico · 7 shared papers, 2016–2026 · strength 1.15
  2. Mark Joseph Truty · 3 shared papers, 2025–2026 · strength 0.76
  3. Robert R. McWilliams · 4 shared papers, 2020–2026 · strength 0.67
  4. Tanios Bekaii‐Saab · 4 shared papers, 2020–2026 · strength 0.55
  5. Khalid Jazieh · 2 shared papers, 2026 · strength 0.50
  6. Kari G. Rabe · 2 shared papers, 2025–2026 · strength 0.49
  7. Samuel O. Antwi · 2 shared papers, 2025–2026 · strength 0.49
  8. Ann L. Oberg · 2 shared papers, 2025–2026 · strength 0.49
  9. Cornelius A. Thiels · 2 shared papers, 2025–2026 · strength 0.43
  10. Sean Patrick Cleary · 2 shared papers, 2025 · strength 0.42
  11. Thorvardur Ragnar Halfdanarson · 2 shared papers, 2024–2025 · strength 0.38
  12. Amit Mahipal · 2 shared papers, 2024–2025 · strength 0.38
  13. Alexander Dean Sherry · 1 shared paper, 2025 · strength 0.33
  14. Alexandra K. Bennett · 1 shared paper, 2025 · strength 0.33
  15. Krishan R. Jethwa · 1 shared paper, 2025 · strength 0.33
  16. Rondell Patrell Graham · 2 shared papers, 2020–2025 · strength 0.28
  17. Jason W. Hoskins · 1 shared paper, 2026 · strength 0.27
  18. Katelyn E. Connelly · 1 shared paper, 2026 · strength 0.27
  19. Laufey Thora Amundadottir · 1 shared paper, 2026 · strength 0.27
  20. Hugues Sicotte · 1 shared paper, 2026 · strength 0.27
  21. Ezequiel J. Tolosa · 2 shared papers, 2020–2025 · strength 0.27
  22. Alex A. Adjei · 2 shared papers, 2020–2024 · strength 0.25
  23. Christopher Hartley · 1 shared paper, 2026 · strength 0.23
  24. Luis Humberto Cisneros · 1 shared paper, 2026 · strength 0.23
  25. Ben George · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.